JP Morgan Chase
TBPH

JP Morgan Chase’s Theravance Biopharma TBPH Stock Holding History

JP Morgan Chase’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,300
Closed -$440K – 6791
2021
Q2 		$440K Buy
30,300
+15,000
+98% +$282K ﹤0.01% 4774
2021
Q1 		$312K Buy
+15,300
New +$291K ﹤0.01% 4947
2018
Q4 		– Sell
-30,000
Closed -$980K – 5936
2018
Q3 		$980K Buy
+30,000
New +$818K ﹤0.01% 3934

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

JP Morgan Chase's TBPH Position: Q2 2026 in Review

JP Morgan Chase increased its Theravance Biopharma (TBPH) stake by 74% in Q2 2026, buying an estimated $1.57M and bringing the position to 221,846 shares worth $3.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3697.

JP Morgan Chase first reported a position in TBPH in Q4 2015 and has held it in 43 quarters since. The position peaked at $7.79M in Q4 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • JP Morgan Chase held 221,846 shares of Theravance Biopharma worth $3.78M as of Q2 2026.
  • JP Morgan Chase bought 94,579 Theravance Biopharma shares in Q2 2026, an estimated $1.57M.
  • Theravance Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3697 holding.
  • JP Morgan Chase first reported a position in Theravance Biopharma in Q4 2015 and has held it in 43 quarters since.
  • JP Morgan Chase's Theravance Biopharma position peaked at $7.79M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.